A double-blind trial of fluoxetine in pathologic skin picking

Daphne Simeon, Dan J. Stein, Shira Gross, Nazrul Islam, James Schmeidler, Eric Hollander

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Background: Our objective was to determine the efficacy of fluoxetine in the treatment of pathologic skin picking in a double-blind, placebo- controlled, parallel trial. Method: Twenty-one adults with chronic pathologic skin picking agreed to participate and received 10 weeks of placebo or fluoxetine with a flexible dosing schedule up to 80 mg/day. Three skin- picking measures were employed: the Clinical Global Impression-Improvement (CGI-I) scale, the Skin Picking Treatment Scale (SPTS), and a visual analog scale of self-rated change (VAS). In addition, depression, anxiety, and obsessions-compulsions were rated using the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety (HAM-A), the Spielberger State-Trait Anxiety Inventory (STAI), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) for the duration of the study. Results: Seventeen subjects (6 treated with fluoxetine and II treated with placebo) completed the trial, at a mean fluoxetine dose of 55 mg/day. Fluoxetine was significantly superior to placebo in the treatment of skin picking according to two of the three measures for the completer analysis and to one of the three measures for the intent-to-treat analysis. Neither baseline level nor change in depression, anxiety, or obsessive-compulsive symptoms was significantly related to change in skin picking. Conclusion: This first controlled trial of the treatment of pathologic skin picking suggests that fluoxetine may be of therapeutic benefit. Larger controlled studies are warranted.

Original languageEnglish (US)
Pages (from-to)341-347
Number of pages7
JournalJournal of Clinical Psychiatry
Volume58
Issue number8
StatePublished - Aug 1997
Externally publishedYes

Fingerprint

Fluoxetine
Skin
Anxiety
Placebos
Depression
Therapeutics
Obsessive Behavior
Visual Analog Scale
Appointments and Schedules
Equipment and Supplies

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Simeon, D., Stein, D. J., Gross, S., Islam, N., Schmeidler, J., & Hollander, E. (1997). A double-blind trial of fluoxetine in pathologic skin picking. Journal of Clinical Psychiatry, 58(8), 341-347.

A double-blind trial of fluoxetine in pathologic skin picking. / Simeon, Daphne; Stein, Dan J.; Gross, Shira; Islam, Nazrul; Schmeidler, James; Hollander, Eric.

In: Journal of Clinical Psychiatry, Vol. 58, No. 8, 08.1997, p. 341-347.

Research output: Contribution to journalArticle

Simeon, D, Stein, DJ, Gross, S, Islam, N, Schmeidler, J & Hollander, E 1997, 'A double-blind trial of fluoxetine in pathologic skin picking', Journal of Clinical Psychiatry, vol. 58, no. 8, pp. 341-347.
Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathologic skin picking. Journal of Clinical Psychiatry. 1997 Aug;58(8):341-347.
Simeon, Daphne ; Stein, Dan J. ; Gross, Shira ; Islam, Nazrul ; Schmeidler, James ; Hollander, Eric. / A double-blind trial of fluoxetine in pathologic skin picking. In: Journal of Clinical Psychiatry. 1997 ; Vol. 58, No. 8. pp. 341-347.
@article{70c9ecfcc8244f0c90cadf1333a885ea,
title = "A double-blind trial of fluoxetine in pathologic skin picking",
abstract = "Background: Our objective was to determine the efficacy of fluoxetine in the treatment of pathologic skin picking in a double-blind, placebo- controlled, parallel trial. Method: Twenty-one adults with chronic pathologic skin picking agreed to participate and received 10 weeks of placebo or fluoxetine with a flexible dosing schedule up to 80 mg/day. Three skin- picking measures were employed: the Clinical Global Impression-Improvement (CGI-I) scale, the Skin Picking Treatment Scale (SPTS), and a visual analog scale of self-rated change (VAS). In addition, depression, anxiety, and obsessions-compulsions were rated using the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety (HAM-A), the Spielberger State-Trait Anxiety Inventory (STAI), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) for the duration of the study. Results: Seventeen subjects (6 treated with fluoxetine and II treated with placebo) completed the trial, at a mean fluoxetine dose of 55 mg/day. Fluoxetine was significantly superior to placebo in the treatment of skin picking according to two of the three measures for the completer analysis and to one of the three measures for the intent-to-treat analysis. Neither baseline level nor change in depression, anxiety, or obsessive-compulsive symptoms was significantly related to change in skin picking. Conclusion: This first controlled trial of the treatment of pathologic skin picking suggests that fluoxetine may be of therapeutic benefit. Larger controlled studies are warranted.",
author = "Daphne Simeon and Stein, {Dan J.} and Shira Gross and Nazrul Islam and James Schmeidler and Eric Hollander",
year = "1997",
month = "8",
language = "English (US)",
volume = "58",
pages = "341--347",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - A double-blind trial of fluoxetine in pathologic skin picking

AU - Simeon, Daphne

AU - Stein, Dan J.

AU - Gross, Shira

AU - Islam, Nazrul

AU - Schmeidler, James

AU - Hollander, Eric

PY - 1997/8

Y1 - 1997/8

N2 - Background: Our objective was to determine the efficacy of fluoxetine in the treatment of pathologic skin picking in a double-blind, placebo- controlled, parallel trial. Method: Twenty-one adults with chronic pathologic skin picking agreed to participate and received 10 weeks of placebo or fluoxetine with a flexible dosing schedule up to 80 mg/day. Three skin- picking measures were employed: the Clinical Global Impression-Improvement (CGI-I) scale, the Skin Picking Treatment Scale (SPTS), and a visual analog scale of self-rated change (VAS). In addition, depression, anxiety, and obsessions-compulsions were rated using the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety (HAM-A), the Spielberger State-Trait Anxiety Inventory (STAI), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) for the duration of the study. Results: Seventeen subjects (6 treated with fluoxetine and II treated with placebo) completed the trial, at a mean fluoxetine dose of 55 mg/day. Fluoxetine was significantly superior to placebo in the treatment of skin picking according to two of the three measures for the completer analysis and to one of the three measures for the intent-to-treat analysis. Neither baseline level nor change in depression, anxiety, or obsessive-compulsive symptoms was significantly related to change in skin picking. Conclusion: This first controlled trial of the treatment of pathologic skin picking suggests that fluoxetine may be of therapeutic benefit. Larger controlled studies are warranted.

AB - Background: Our objective was to determine the efficacy of fluoxetine in the treatment of pathologic skin picking in a double-blind, placebo- controlled, parallel trial. Method: Twenty-one adults with chronic pathologic skin picking agreed to participate and received 10 weeks of placebo or fluoxetine with a flexible dosing schedule up to 80 mg/day. Three skin- picking measures were employed: the Clinical Global Impression-Improvement (CGI-I) scale, the Skin Picking Treatment Scale (SPTS), and a visual analog scale of self-rated change (VAS). In addition, depression, anxiety, and obsessions-compulsions were rated using the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety (HAM-A), the Spielberger State-Trait Anxiety Inventory (STAI), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) for the duration of the study. Results: Seventeen subjects (6 treated with fluoxetine and II treated with placebo) completed the trial, at a mean fluoxetine dose of 55 mg/day. Fluoxetine was significantly superior to placebo in the treatment of skin picking according to two of the three measures for the completer analysis and to one of the three measures for the intent-to-treat analysis. Neither baseline level nor change in depression, anxiety, or obsessive-compulsive symptoms was significantly related to change in skin picking. Conclusion: This first controlled trial of the treatment of pathologic skin picking suggests that fluoxetine may be of therapeutic benefit. Larger controlled studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0030869328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030869328&partnerID=8YFLogxK

M3 - Article

C2 - 9515971

AN - SCOPUS:0030869328

VL - 58

SP - 341

EP - 347

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -